Boundless Bio Inc. BOLD 深 滬
等待開盤 04-02 09:30:00 美东时间
1.14
+0.040
+3.64%
華盛通- 最 高1.16
- 今 開1.10
- 成交量 2.69万股
- 最 低 1.10
- 昨 收 1.10
- 總市值 2554.43万
- 52周最高 1.78
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 0.9612
- 委 比 32.61%
- 總股本 2240.73万
- 歷史最高 15.24
- 量 比 0.41
- 振 幅 5.45%
- 歷史最低 0.9612
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Boundless Bio To Present Oral Kinesin Degrader Program At The AACR Annual Meeting 2026
Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
03-18 04:55
Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 21.62 percent increase over losses of $(0.74) per share from
03-09 19:13
Boundless Bio CEO Zachary Hornby to Join Fireside Chat at Leerink Global Healthcare Conference
Boundless Bio CEO Zachary Hornby to Join Fireside Chat at Leerink Global Healthcare Conference Boundless Bio (Nasdaq: BOLD) said its President and CEO Zachary Hornby will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 11:20 a.m. ET in Miami
03-04 20:02
Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study....
01-17 00:31
Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer
Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies (ecDTx). The company highlights the significant unmet me...
2025-11-11 02:51
Boundless Bio Q3 EPS $(0.62) Misses $(0.53) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.53) by 16.32 percent. This is a 16.22 percent increase over losses of $(0.74) per share from
2025-11-05 20:08
Boundless Bio posts Q3 net loss of $13.9 million on $117.6 million cash balance
Boundless Bio Inc. reported a cash, cash equivalents, and short-term investments balance of $117.6 million as of September 30, 2025. Research and development expenses for the third quarter of 2025 wer...
2025-11-05 20:01
Boundless Bio To Present Preclinical Data On BBI-825 And BBI-355 Combo Targeting Oncogene-Amplified Cancers At AACR-NCI-EORTC 2025
Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
2025-10-14 04:10
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company, will present a poster at the AACR-NCI-EORTC conference in Boston from October 22-26, 2025. The presentation will focus on the synergistic oral combination of BBI-825 and BBI-355, targeting oncogene amplified cancers. BBI-825 is a selective RNR inhibitor, while BBI-355 is a selective CHK1 inhibitor. Both compounds are being evaluated in the phase 1/2 POTENTIATE trial. Boundless Bio s...
2025-10-13 20:05
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price target from $5 to $4.
2025-08-11 18:43
